He’s gotten a lot of press attention and it’s great, but it’s not something new. The researchers who do GBM work are always looking at developments in the parallel tracks of other cancers. It’s not really the case that they haven’t looked at melanoma work. That’s sort of a news spin on the nature of this work. There’s always cross-pollination because the genetic underpinnings of cancers are almost always related. For example, IDH inhibitors (the most recent advancements for glioma patients) are relevant for several kinds of cancer, not just gliomas.